RxDoctor Payments DataLook up a doctor →

Christine Rieger

Psychiatric/Mental Health · Escondido, CANPI 1861921926

Payments from drug & device makers

$10,399in general payments, 2019–2025

Across 479 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$942
  • Vanda Pharmaceuticals Inc.$879
  • Teva Pharmaceuticals USA, Inc.$778
  • Alkermes, Inc.$768
  • Johnson & Johnson$744
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$10,22698%
  • Education$1732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,399 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$15,544
Medicare patients
39
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil46$130,705
Invega SustennaPaliperidone Palmitate39$123,884
VraylarCariprazine Hcl62$89,681
CaplytaLumateperone Tosylate52$83,559
RexultiBrexpiprazole20$20,481
TrintellixVortioxetine Hydrobromide37$18,662
SeroquelQuetiapine Fumarate11$15,962
LinzessLinaclotide19$10,933
Chlorpromazine Hcl29$8,647
Topiramate ErTopiramate12$5,588
Lurasidone Hcl27$4,540
Clozapine86$4,309
Bupropion XlBupropion Hcl46$4,169
Olanzapine139$2,837
Aripiprazole58$2,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$768$130,70546 claims
Johnson & JohnsonInvega Sustenna$744$123,88439 claims
AbbVieVraylar, Linzess$942$100,61481 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,343$83,55952 claims
Otsuka America Pharmaceutical, Inc.Rexulti$739$20,48120 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$108$18,66237 claims
AstraZenecaSeroquel$132$15,96211 claims
Lilly USA, LLCOlanzapine$181$2,837139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Escondido

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →